|
|
|
|
| LEADER |
01582nam a2200265Ia 4500 |
| 001 |
10.3892-ol.2022.13365 |
| 008 |
220718s2022 CNT 000 0 und d |
| 020 |
|
|
|a 17921074 (ISSN)
|
| 245 |
1 |
0 |
|a B-cell lymphoma-associated hemophagocytic lymphohistiocytosis: A case report
|
| 260 |
|
0 |
|b Spandidos Publications
|c 2022
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.3892/ol.2022.13365
|
| 520 |
3 |
|
|a Hemophagocytic lymphohistiocytosis (HLH) is a life‑threatening condition characterized by an exaggerated but dysregulated immune response resulting in hyperinflam‑ mation, with a potential for progression to multiple organ dysfunction and failure. Infectious diseases, inflammatory disorders, malignancies and immunodeficiency syndromes are known triggers of HLH in adults. The present study reported the case of a middle‑aged man with HLH triggered by B‑cell lymphoma who was successfully treated with dexametha‑ sone; etoposide, prednisone, vincristine, cyclophosphamide, hydroxy‑doxorubicin and rituximab chemotherapy; and multiple intrathecal methotrexate with a good outcome. © 2022 Spandidos Publications. All rights reserved.
|
| 650 |
0 |
4 |
|a B-cell lymphoma
|
| 650 |
0 |
4 |
|a chemotherapy
|
| 650 |
0 |
4 |
|a hemophagocytic histiocytosis
|
| 650 |
0 |
4 |
|a hyperinflammation
|
| 700 |
1 |
|
|a Amina, B.O.T.
|e author
|
| 700 |
1 |
|
|a Asemota, J.
|e author
|
| 700 |
1 |
|
|a Laziuk, K.
|e author
|
| 700 |
1 |
|
|a Ojo, A.S.
|e author
|
| 700 |
1 |
|
|a Ojukwu, S.
|e author
|
| 700 |
1 |
|
|a Rajeh, A.
|e author
|
| 700 |
1 |
|
|a Saleh, M.
|e author
|
| 700 |
1 |
|
|a Smith, C.J.
|e author
|
| 773 |
|
|
|t Oncology Letters
|
